Abstract
Objective
Blood and urine concentrations of hormones are implicated in the etiology of some cancers. Small studies have assessed relationships between production of the daidzein metabolites equol and O-desmethylangolensin (ODMA) and hormones, but findings are unclear. We evaluated relationships between daidzein-metabolizing phenotypes and follicular phase concentrations of estrogens, androgens, sex hormone binding globulin (SHBG), and urinary estrogen metabolites in premenopausal women.
Methods
Two-hundred women collected a first-void urine sample after a 3-day soy challenge, and 191 and 193 provided fasting blood and spot urine samples, respectively, during days 5–9 of their menstrual cycle. Soy challenge urines were analyzed for isoflavones; serum was analyzed for estrogens, androgens, and SHBG; spot urines were analyzed for 2-hydroxyestrone and 16α-hydroxyestrone. Data were log-transformed and multiple regression analyses were conducted to assess relationships between daidzein-metabolizing phenotypes and hormones and SHBG. Data from 187 and 189 women were included in analyses of serum and urine hormones, respectively.
Results
55 (27.5%) and 182 (91%) of the 200 women who provided a soy challenge urine sample were equol- and ODMA-producers (>87.5 ng/ml urine), respectively. In unadjusted analyses, equol-producers (n = 52) had lower free testosterone than equol non-producers (n = 137, p = 0.02). In adjusted analyses, there were no differences between producers and non-producers of either daidzein metabolite.
Conclusions
In the absence of a soy intervention, we found no difference in serum or urine hormone concentrations between producers and non-producers of equol or ODMA.
Similar content being viewed by others
References
Persson I (2000) Estrogens in the causation of breast, endometrial and ovarian cancers—evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 74:357–364. doi:10.1016/S0960–0760(00)00113-8
Stewart EA (2001) Uterine fibroids. Lancet 357:293–298. doi:10.1016/S0140-6736(00)03622-9
Giudice LC, Kao LC (2004) Endometriosis. Lancet 364:1789–1799. doi:10.1016/S0140-6736(04)17403-5
Muti P, Bradlow HL, Micheli A et al (2000) Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology 11:635–640. doi:10.1097/00001648-200011000-00004
Kabat GC, Chang CJ, Sparano JA et al (1997) Urinary estrogen metabolites and breast cancer: a case–control study. Cancer Epidemiol Biomarkers Prev 6:505–509
Meilahn EN, De Stavola B, Allen DS et al (1998) Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer 78:1250–1255
Zheng W, Dunning L, Jin F, Holtzman J (1998) Correspondence re: Kabat GC et al., Urinary estrogen metabolites and breast cancer: a case–control study. Cancer Epidemiol Biomark Prev 6:505–509, 1997. Cancer Epidemiol Biomarkers Prev 7:85–86
Kurzer MS (2002) Hormonal effects of soy in premenopausal women and men. J Nutr 132:570S–573S
Kurzer MS (2000) Hormonal effects of soy isoflavones: studies in premenopausal and postmenopausal women. J Nutr 130:660S–661S
Setchell KD, Brown NM, Lydeking-Olsen E (2002) The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577–3584
Rowland IR, Wiseman H, Sanders TA, Adlercreutz H, Bowey EA (2000) Interindividual variation in metabolism of soy isoflavones and lignans: influence of habitual diet on equol production by the gut microflora. Nutr Cancer 36:27–32. doi:10.1207/S15327914NC3601_5
Akaza H, Miyanaga N, Takashima N et al (2002) Is daidzein non-metabolizer a high risk for prostate cancer? A case–controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 32:296–300. doi:10.1093/jjco/hyf064
Kelly GE, Joannou GE, Reeder AY, Nelson C, Waring MA (1995) The variable metabolic response to dietary isoflavones in humans. Proc Soc Exp Biol Med 208:40–43
Lampe JW, Karr SC, Hutchins AM, Slavin JL (1998) Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 217:335–339
Hutchins AM, Slavin JL, Lampe JW (1995) Urinary isoflavonoid phytoestrogen and lignan excretion after consumption of fermented and unfermented soy products. J Am Diet Assoc 95:545–551. doi:10.1016/S0002-8223(95)00149-2
Arai Y, Uehara M, Sato Y et al (2000) Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol 10:127–135
Frankenfeld CL, McTiernan A, Tworoger SS et al (2004) Serum steroid hormones, sex hormone-binding globulin concentrations, and urinary hydroxylated estrogen metabolites in post-menopausal women in relation to daidzein-metabolizing phenotypes. J Steroid Biochem Mol Biol 88: 399–408. doi:10.1016/j.jsbmb.2004.01.006
Atkinson C, Frankenfeld CL, Lampe JW (2005) Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med (Maywood) 230:155–170
Evans BA, Griffiths K, Morton MS (1995) Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147:295–302
Pelissero C, Lenczowski MJ, Chinzi D, Davail-Cuisset B, Sumpter JP, Fostier A (1996) Effects of flavonoids on aromatase activity, an in vitro study. J Steroid Biochem Mol Biol 57:215–223. doi:10.1016/0960-0760(95)00261-8
Adlercreutz H, Bannwart C, Wahala K et al (1993) Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 44:147–153. doi:10.1016/0960-0760(93)90022-O
Adlercreutz H, Martin F, Pulkkinen M et al (1976) Intestinal metabolism of estrogens. J Clin Endocrinol Metab 43:497–505
Järvenpää P, Kosunen T, Fotsis T, Adlercreutz H (1980) In vitro metabolism of estrogens by isolated intestinal micro-organisms and by human faecal microflora. J Steroid Biochem 13:345–349. doi:10.1016/0022-4731(80)90014-X
Järvenpää P (1990) In vitro metabolism of catechol estrogens by human fecal microflora. J Steroid Biochem 35:289–292. doi:10.1016/0022-4731(90)90286-2
Lombardi P, Goldin B, Boutin E, Gorbach SL (1978) Metabolism of androgens and estrogens by human fecal microorganisms. J Steroid Biochem 9:795–801. doi:10.1016/0022-4731(78)90203-0
Ingram D, Sanders K, Kolybaba M, Lopez D (1997) Case–control study of phyto-oestrogens and breast cancer. Lancet 350:990–994. doi:10.1016/S0140-6736(97)01339-1
Zheng W, Dai Q, Custer LJ et al (1999) Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 8:35–40
Grace PB, Taylor JI, Low YL et al (2004) Phytoestrogen concentrations in serum and spot urine as biomarkers for dietary phytoestrogen intake and their relation to breast cancer risk in European prospective investigation of cancer and nutrition-norfolk. Cancer Epidemiol Biomarkers Prev 13:698–708
Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS (2000) Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9:581–586
Bonorden MJ, Greany KA, Wangen KE et al (2004) Consumption of Lactobacillus acidophilus and Bifidobacterium longum do not alter urinary equol excretion and plasma reproductive hormones in premenopausal women. Eur J Clin Nutr 58:1635–1642. doi:10.1038/sj.ejcn.1602020
Atkinson C, Newton KM, Aiello-Bowles EJ, Yong M, Lampe JW (2008) Demographic, anthropometric, and lifestyle factors and dietary intakes in relation to daidzein-metabolizing phenotypes among premenopausal women in the United States. Am J Clin Nutr 87:679–687
Taplin SH, Ichikawa L, Buist DS, Seger D, White E (2004) Evaluating organized breast cancer screening implementation: the prevention of late-stage disease? Cancer Epidemiol Biomarkers Prev 13:225–234. doi:10.1158/1055-9965.EPI-03-0206
Goebelsmann U, Bernstein GS, Gale JA et al (1979) Serum gonadotrophin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In: Lepow IH, Crozier R (eds) Vasectomy: Immunologic and pathophysiologic effects in animals and man. New York, Academic Press, p 165
Probst-Hensch NM, Ingles SA, Diep AT et al (1999) Aromatase and breast cancer susceptibility. Endocr Relat Cancer 6:165–173. doi:10.1677/erc.0.0060165
Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666–3672. doi:10.1210/jc.84.10.3666
Sodergard R, Backstrom T, Shanbhag V, Carstensen H (1982) Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 16:801–810. doi:10.1016/0022-4731(82)90038-3
Rinaldi S, Geay A, Dechaud H et al (2002) Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 11:1065–1071
Nettleton JA, Greany KA, Thomas W, Wangen KE, Adlercreutz H, Kurzer MS (2005) The effect of soy consumption on the urinary 2:16-hydroxyestrone ratio in postmenopausal women depends on equol production status but is not influenced by probiotic consumption. J Nutr 135:603–608
Mulligan AA, Welch AA, McTaggart AA, Bhaniani A, Bingham SA (2007) Intakes and sources of soya foods and isoflavones in a UK population cohort study (EPIC-Norfolk). Eur J Clin Nutr 61:248–254. doi:10.1038/sj.ejcn.1602509
Keinan-Boker L, van Der Schouw YT, Grobbee DE, Peeters PH (2004) Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 79:282–288
McKinlay SM, Brambilla DJ, Posner JG (1992) The normal menopause transition. Maturitas 14:103–115. doi:10.1016/0378-5122(92)90003-M
McKinlay SM (1996) The normal menopause transition: an overview. Maturitas 23:137–145. doi:10.1016/0378-5122(95)00985-X
Burger HG, Dudley EC, Hopper JL et al (1999) Prospectively measured levels of serum follicle-stimulating hormone, estradiol, and the dimeric inhibins during the menopausal transition in a population-based cohort of women. J Clin Endocrinol Metab 84:4025–4030. doi:10.1210/jc.84.11.4025
Burger HG, Dudley EC, Robertson DM, Dennerstein L (2002) Hormonal changes in the menopause transition. Recent Prog Horm Res 57:257–275. doi:10.1210/rp.57.1.257
Acknowledgments
We wish to thank Kathy Plant, Kelly Ehrlich, and the GH group for screening interviews, clinic visits and study coordination, Wendy Thomas for isoflavone analyses, JoAnn Prunty for creatinine analyses, and all of the study participants.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by the National Institute of Health (R01CA97366 and U01CA63731).
Rights and permissions
About this article
Cite this article
Atkinson, C., Newton, K.M., Stanczyk, F.Z. et al. Daidzein-metabolizing phenotypes in relation to serum hormones and sex hormone binding globulin, and urinary estrogen metabolites in premenopausal women in the United States. Cancer Causes Control 19, 1085–1093 (2008). https://doi.org/10.1007/s10552-008-9172-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10552-008-9172-3